<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ911028-0110</DOCNO><DOCID>911028-0110.</DOCID><HL>   Former Parke-Davis   Scientist Pleads Guilty   To Selling Drug Data</HL><DATE>10/28/91</DATE><SO>WALL STREET JOURNAL (J), PAGE A7</SO><CO>   WLA</CO><MS>CONSUMER NON-CYCLICAL (NCY)</MS><IN>BANKRUPTCIES (BCY)DRUG MANUFACTURERS (DRG)</IN><NS>BANKRUPTCY DECLARATIONS AND PROCEEDINGS (BCY)</NS><GV>FOOD AND DRUG ADMINISTRATION (FDA)JUSTICE DEPARTMENT (JUS)</GV><RE>MARYLAND (MD)NEW JERSEY (NJ)NORTH AMERICA (NME)UNITED STATES (US)</RE><LP>   BALTIMORE -- John E. Botzolakis, former senior scientistof Warner-Lambert Co.'s Parke-Davis Co. unit, pleaded guiltyto selling the classified formulas of two drugs, said theU.S. attorney's office.   Officials said Mr. Botzolakis, who was charged last monthwith conspiracy to transport stolen property in interstatecommerce, entered a guilty plea to federal Judge John R.Hargrove here. He faces a maximum penalty of five years inprison and/or a $250,000 fine.</LP><TEXT>   Mr. Botzolakis pleaded guilty to charges that he soldconfidential information on the antibiotic Erythromycin andanxiety treatment Prazepam to a former vice president ofAmerican Therapeutics Inc. for $14,000. Mr. Botzolakis joinedWarner-Lambert in 1984 and left the company in July.   American Therapeutics, a generic drug maker which filedfor bankruptcy-law protection in March, later included thedata in applications submitted to the Food and DrugAdministration. Last year, the company was fined $1 millionfor illegal payments and statements to the FDA.   Officials said the case is part of a continuinginvestigation of the generic drug industry that's beingconducted by the U.S. attorney for Maryland, the JusticeDepartment's Office of Consumer Litigation, the FDA and theFederal Bureau of Investigation. The U.S. attorney saidadditional charges are expected to result from theinvestigation.   An attorney for Mr. Botzolakis declined to comment.</TEXT></DOC>